Crystal structure of Trastuzumab Fc conjugated to Linker-Payload

Crystal structure of Trastuzumab Fc conjugated to Linker-Payload Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, N-({[4-({N-[3-(2,5-dioxopyrrolidin-1-yl)propanoyl]-L-alanyl-L-alanyl}amino)phenyl]methoxy}carbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, ... Authors: Jaime-Garza, M, Noland, C.L, Gabelli, S.B. Deposit date: 2025-10-31 Release date: 2025-12-24 Last modified: 2026-01-14 Method: X-RAY DIFFRACTION (2.46 Å) Cite: Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates. Pharmaceutics, 17, 2025

与接头-有效载荷描述符缀合的曲妥珠单抗Fc段（Trastuzumab Fc）晶体结构：
N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-2)-α-D-吡喃甘露糖(alpha-D-mannopyranose)-(1-3)-[N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-2)-α-D-吡喃甘露糖(alpha-D-mannopyranose)-(1-6)]β-D-吡喃甘露糖(beta-D-mannopyranose)-(1-4)-N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-4)-[α-L-吡喃岩藻糖(alpha-L-fucopyranose)-(1-6)]N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)，N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-4)-α-D-吡喃甘露糖(alpha-D-mannopyranose)-(1-3)-[N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-4)-α-D-吡喃甘露糖(alpha-D-mannopyranose)-(1-6)]β-D-吡喃甘露糖(beta-D-mannopyranose)-(1-4)-N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)-(1-4)-[α-L-吡喃岩藻糖(alpha-L-fucopyranose)-(1-6)]N-乙酰基-2-脱氧-β-D-吡喃葡萄糖胺(2-acetamido-2-deoxy-beta-D-glucopyranose)，N-({[4-({N-[3-(2,5-二氧代吡咯烷-1-基)丙酰基]-L-丙氨酰-L-丙氨酰}氨基)苯基]甲氧基}羰基)-N-甲基-L-缬氨酰-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-羟基-1-苯基丙-2-基]氨基}-1-甲氧基-2-甲基-3-氧代丙基]吡咯烷-1-基}-3-甲氧基-5-甲基-1-氧代庚烷-4-基]-N-甲基-L-缬氨酰胺，……
作者：Jaime-Garza, M, Noland, C.L, Gabelli, S.B.
存储日期：2025年10月31日
发布日期：2025年12月24日
最后修改日期：2026年1月14日
检测方法：X射线衍射（X-RAY DIFFRACTION），分辨率2.46埃
引用文献：《抗体药物偶联物位点特异性缀合物中的接头屏蔽结构表征》（Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates），《药剂学》（Pharmaceutics），17，2025